SCHEMBL14977008

SCHEMBL14977008

O=C1NC(c2ccc(F)c(F)c2)=COc2ccc(F)cc21

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.42
FABP6 P51161 1/20 0.40
TDP2 O95551 3/20 0.40
PDE3B Q13370 3/20 0.36
PDE3A Q14432 3/20 0.36
GRM5 P41594 1/20 0.35
PARP1 P09874 2/20 0.34
PARP3 Q9Y6F1 1/20 0.34
PGR P06401 2/20 0.33
NR3C2 P08235 1/20 0.33
MEN1 O00255 1/20 0.31
PRKD3 O94806 1/20 0.31
EGFR P00533 1/20 0.31
PRKCG P05129 1/20 0.31
PRKCB P05771 1/20 0.31
SRC P12931 1/20 0.31
PRKCA P17252 1/20 0.31
PRKCH P24723 1/20 0.31
PRKCI P41743 1/20 0.31
PRKCE Q02156 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16227295 0.88 MAPT (0.49) MAPTFABP6TDP2PDE3BPDE3A
SCHEMBL14976463 0.86 MAPT (0.45) MAPTFABP6TDP2TDP1NPC1
SCHEMBL14977373 0.86 MAPT (0.45) MAPTFABP6TDP2PARP1PARP3
SCHEMBL14976563 0.85 TDP2 (0.51) MAPTFABP6TDP2PARP1PARP3
SCHEMBL16227213 0.84 MAPT (0.40) MAPTFABP6TDP2PARP1PARP3
SCHEMBL854525 0.83 MAPT (0.50) MAPTFABP6TDP2
SCHEMBL14976868 0.83 MAPK1 (0.44) MAPTFABP6TDP2PARP1MEN1
SCHEMBL9930835 0.83 TDP2 (0.43) MAPTFABP6TDP2PGRMEN1
SCHEMBL14976068 0.83 FABP6 (0.50) MAPTFABP6TDP2PARP1PARP3
SCHEMBL14976676 0.81 MAPT (0.41) MAPTFABP6TDP2PDE3BPDE3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2788328-B1 3-PHENYL-ISOQUINOLIN-1(2H)-ONE DERIVATIVES AS PARP-1 INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2018-01-31 EP disclosed
US-9422243-B2 3-phenyl-isoquinolin-1(2H)-one derivatives as PARP-1 inhibitors NERVIANO MEDICAL SCIENCES S.R.L. a corporation (IT) 2016-08-23 US disclosed
US-20140336192-A1 3-PHENYL-ISOQUINOLIN-1(2H)-ONE DERIVATIVES AS PARP-1 INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. a corporation 2014-11-13 US disclosed
EP-2788328-A1 3-PHENYL-ISOQUINOLIN-1(2H)-ONE DERIVATIVES AS PARP-1 INHIBITORS Nerviano Medical Sciences S.r.l. (IT) 2014-10-15 EP disclosed
WO-2013076090-A1 3-PHENYL-ISOQUINOLIN-1(2H)-ONE DERIVATIVES AS PARP-1 INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2013-05-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140336192-A1 3-PHENYL-ISOQUINOLIN-1(2H)-ONE DERIVATIVES AS PARP-1 INHIBITORS PARP1, PARP2, PARP11 MAPT 1066/4885FABP6 3856/4885TDP2 100/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.